Form 4: Outset Medical Director D. Keith Grossman Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director D. Keith Grossman exercised stock options and sold shares of Outset Medical (OM) common stock on June 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 3, 2024, D. Keith Grossman, a director of Outset Medical, Inc. (OM), executed non-qualified stock options and sold shares of common stock.
• The transactions were carried out under a Rule 10b5-1 trading plan adopted on August 7, 2023.
• Grossman exercised options to acquire 31,186 shares and 38,117 shares at an exercise price of $1.11 per share.
• He then sold 26,230 shares at a weighted average price of $3.8035 and 11,887 shares at a weighted average price of $3.7409.
• Following these transactions, Grossman directly owns 74,035 shares and indirectly owns 5,186 shares through the Grossman Fam Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives and directors to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the transactions are unusually large or signal a change in the insider's view of the company's prospects.

Comparison to Industry Standards

• Insider transactions are a normal part of corporate governance.
• Companies like Medtronic, Baxter, and DaVita are also subject to similar insider trading regulations and reporting requirements.
• The use of 10b5-1 plans is a common practice among executives in publicly traded companies to manage their stock holdings while avoiding accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates